ZVSA Stock Overview A clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
ZyVersa Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ZyVersa Therapeutics Historical stock prices Current Share Price US$1.24 52 Week High US$25.00 52 Week Low US$0.98 Beta 0.37 1 Month Change 21.57% 3 Month Change -44.64% 1 Year Change -85.91% 3 Year Change n/a 5 Year Change n/a Change since IPO -99.96%
Recent News & Updates
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Nov 21
ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board Oct 07 ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.397396 million. Sep 18
ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 29, 2024 Sep 02
ZyVersa Therapeutics, Inc. Announces Publish Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation Aug 08
ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease Mar 20 See more updates
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Nov 21
ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board Oct 07 ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.397396 million. Sep 18
ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 29, 2024 Sep 02
ZyVersa Therapeutics, Inc. Announces Publish Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation Aug 08
ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease Mar 20
ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4) Mar 09 ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market Mar 04
ZyVersa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.99964 million. Dec 12
Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii) Nov 19
Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii) Nov 18
High number of new and inexperienced directors Nov 15
ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering. Nov 05 ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering. Nov 04
ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection Nov 02
ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease Oct 26
ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues Oct 06
Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues Sep 23
Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases Sep 13
ZyVersa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Sep 10
ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023 Aug 22 ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 31, 2023
ZyVersa Therapeutics, Inc. announced delayed 10-Q filing Aug 17
ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease Jul 08
ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease Jun 23
ZyVersa Therapeutics Receives Non-Compliance Letter Form Nasdaq Jun 13
European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease Jun 07
ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors May 20
ZyVersa Therapeutics, Inc. Appoints Dr. Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs Jan 28
Less than half of directors are independent Jan 12
ZyVersa Therapeutics, Inc. Announces Executive Changes Jan 06
ZyVersa Therapeutics, Inc. Adds Two Esteemed Leaders to Its Renal Scientific Advisory Board Jan 04
High number of new directors Dec 31
No independent directors Dec 14
ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. (NasdaqGM:LSPR) from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction. Dec 14 Shareholder Returns ZVSA US Biotechs US Market 7D 7.8% -1.9% -2.8% 1Y -85.9% -5.7% 24.1%
See full shareholder returns
Return vs Industry: ZVSA underperformed the US Biotechs industry which returned -5.7% over the past year.
Return vs Market: ZVSA underperformed the US Market which returned 24.1% over the past year.
Price Volatility Is ZVSA's price volatile compared to industry and market? ZVSA volatility ZVSA Average Weekly Movement 18.8% Biotechs Industry Average Movement 10.9% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ZVSA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ZVSA's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
Show more ZyVersa Therapeutics, Inc. Fundamentals Summary How do ZyVersa Therapeutics's earnings and revenue compare to its market cap? ZVSA fundamental statistics Market cap US$2.56m Earnings (TTM ) -US$21.33m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ZVSA income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$21.33m Earnings -US$21.33m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 22:30 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ZyVersa Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert LeBoyer NOBLE Capital Markets, Inc.
Show 0 more analysts 